ADAP News and Press, Adaptimmune Therapeutics plc From 05/16/22

- New next-gen SPEAR T-cells (ADP-A2M4N7X19) designed to enhance depth and durability of clinical response demonstrated enhanced proliferation, survival, and recruitment of immune cells in vitro - - Engineered TILs (ADP-TILIL7) intended to improve clinical responses, produced levels o...

The following slide deck was published by Adaptimmune Therapeutics plc in conjunction with their 2022 Q1 earnings call. For further details see: Adaptimmune Therapeutics plc 2022 Q1 - Results - Earnings Call Presentation

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...

Adaptimmune Therapeutics plc (ADAP) Q1 2022 Earnings Conference Call May 09, 2022 8:00 AM ET Company Participants Juli Miller – Head-Investor Relations Adrian Rawcliffe – Chief Executive Officer Gavin Wood – Chief Financial Officer Helen Tayton-Martin – Chief Busin...

Adaptimmune press release (NASDAQ:ADAP): Q1 GAAP EPS of -$0.05 beats by $0.19. Revenue of $3.6M (+737.2% Y/Y) misses by $1.4M. For further details see: Adaptimmune GAAP EPS of -$0.05 beats by $0.19, revenue of $3.6M misses by $1.4M

PHILADELPHIA and OXFORDSHIRE, United Kingdom, May 04, 2022 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announces the appointment of Dr. Joanna (Jo) Brewer as Chief Scientific Officer (CSO) effective immediately. &#x...

PHILADELPHIA and OXFORDSHIRE, United Kingdom, April 28, 2022 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report financial results and provide business updates for the first quarter ended March 31, 2022, before the US markets...

Implementing an appropriate strategy would capture the most profits. One such strategy is diversification. A promising stock for your portfolio to diversify is Alpine Immune Science. As a rising leader in immuno-oncology, Alpine has great medicines and has thus been able to secure thr...

Adaptimmune Therapeutics (NASDAQ:ADAP) is up 15% in trading on Wednesday and up ~21% since Monday's close as a likely beneficiary of Regeneron Pharmaceuticals' (REGN) $250M acquisition of Checkmate Pharmaceuticals (CMPI) announced Tuesday. Like Checkmate (CMPI), ...

Shares of the small-cap cancer companies Adaptimmune Therapeutics (NASDAQ: ADAP) , Agenus (NASDAQ: AGEN) , and Sorrento Therapeutics (NASDAQ: SRNE) all rose by more than 5% during Tuesday's trading session. Adaptimmune, Agenus, and Sorrento appear to be getting a muc...